Vanda Pharmaceuticals (VNDA) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free VNDA Stock Alerts $4.48 -0.08 (-1.75%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineUPDATE 1-Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offerfinance.yahoo.com - April 25 at 1:44 PMShareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offerreuters.com - April 25 at 9:02 AMShareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticalsfinance.yahoo.com - April 25 at 8:44 AMVanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Knowfinance.yahoo.com - April 24 at 10:43 PMVanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigationprnewswire.com - April 22 at 7:13 PMUS Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetliozmsn.com - April 22 at 6:54 PMU.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patentsmsn.com - April 22 at 1:53 PMUS Supreme Court reportedly declines to hear Vanda patent casemsn.com - April 22 at 1:53 PMVanda Pharmaceuticals (NASDAQ:VNDA) Cut to Hold at StockNews.comamericanbankingnews.com - April 22 at 2:16 AMButler Hall Capital urges Vanda to engage in sales discussionsreuters.com - April 19 at 1:12 PMFuture Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cashfinance.yahoo.com - April 18 at 8:56 AMD.C. biotech adopts poison pill after rejecting acquisition offerbizjournals.com - April 18 at 8:56 AMVanda Pharma Adopts Limited Duration Stockholder Rights Plan; Stock Upmarkets.businessinsider.com - April 18 at 12:51 AMWhy Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Sessionbenzinga.com - April 17 at 2:50 PMBiggest stock movers today: ADSK, VNDA, UAL, JBHT, and moremsn.com - April 17 at 2:50 PMCrude Oil Dips 3%; U.S. Bancorp Profit Tops Viewsmarkets.businessinsider.com - April 17 at 2:50 PMNeuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Sharefinance.yahoo.com - April 17 at 2:50 PMWhy Vanda Pharmaceuticals Stock Is Skyrocketing Todayfool.com - April 17 at 11:53 AMVanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Planprnewswire.com - April 17 at 10:21 AMVanda Pharmaceuticals (VNDA) Price Target Increased by 23.53% to 5.36msn.com - April 17 at 9:49 AMVanda Pharma Rejects Future Pak's Takeover Proposals; Stock Climbsmarkets.businessinsider.com - April 17 at 9:49 AMVanda Pharmaceuticals jumps 38% on Future Pak's latest buy offermsn.com - April 17 at 9:49 AMWhy Is Vanda Pharmaceuticals (VNDA) Stock Up 34% Today?msn.com - April 17 at 9:49 AMVanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pakfinance.yahoo.com - April 17 at 9:49 AMVanda Pharmaceuticals rejects takeover proposal from Future Pakreuters.com - April 17 at 9:44 AMVanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pakprnewswire.com - April 17 at 9:02 AMWhy Is Vanda Pharmaceuticals (VNDA) Stock Up 34% Today?investorplace.com - April 17 at 8:32 AM3 Biotech Stocks to Watch for Lucrative Gainsstocknews.com - April 16 at 12:17 PMD.C. biotech scores FDA approval for key drug, stock surgesbizjournals.com - April 3 at 2:50 PMVanda Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:VNDA)marketbeat.com - April 3 at 11:20 AMWhy Is Vanda Pharmaceuticals (VNDA) Stock Up 33% Today?investorplace.com - April 3 at 10:04 AMBiggest stock movers today: CALM, INTC, and moremsn.com - April 3 at 9:49 AMBiotech Catches Major Premarket Bid Following FDA Approvalmsn.com - April 3 at 9:49 AMWhy Is Vanda Pharmaceuticals Stock Trading Higher Today?benzinga.com - April 3 at 9:49 AMVanda Pharmaceuticals shares jump 30% after FDA approval of Fanapt for bipolar I disordermsn.com - April 2 at 9:03 PMUS FDA approves Vanda's drug for bipolar disorderreuters.com - April 2 at 6:15 PMVanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorderprnewswire.com - April 2 at 6:10 PMVanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to Buy at StockNews.commarketbeat.com - March 29 at 11:14 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDAprnewswire.com - March 27 at 7:53 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDAprnewswire.com - March 19 at 6:05 PMLongboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likelyseekingalpha.com - March 16 at 1:27 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDAprnewswire.com - March 11 at 7:55 PMChairman of Vanda Pharmaceuticals Inc (VNDA) Sells Sharesfinance.yahoo.com - March 7 at 3:18 AMVanda Pharmaceuticals Receives CRL From FDA On SNDA For HETLIOZ - Quick Factsmarkets.businessinsider.com - March 6 at 5:17 PMVanda drops as FDA rejects Hetlioz label expansionmsn.com - March 6 at 5:17 PMVanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomniaprnewswire.com - March 6 at 7:00 AMTrexquant Investment LP Raises Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)marketbeat.com - March 5 at 7:53 AMCaxton Associates LP Increases Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)marketbeat.com - March 1 at 8:31 AMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Position Increased by Acadian Asset Management LLCmarketbeat.com - February 23 at 7:35 AMVNDA Sep 2024 3.000 putfinance.yahoo.com - February 17 at 2:21 PM Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). VNDA Media Mentions By Week VNDA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VNDA News Sentiment▼0.160.41▲Average Medical News Sentiment VNDA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VNDA Articles This Week▼112▲VNDA Articles Average Week Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Rigel Pharmaceuticals News Today Verastem News Today Gossamer Bio News Today XOMA News Today Regulus Therapeutics News Today Emergent BioSolutions News Today Lexicon Pharmaceuticals News Today VBI Vaccines News Today AnaptysBio News Today OPKO Health News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VNDA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
